ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / ICCC / options
IMDX (25) TKNO (42) NNNN (35) MYGN (47) ⌘ Pro Terminal β†’

ImmuCell Corporation (ICCC) Options Positioning, Max Pain & Unusual Sweeps

$10.56 +2.92% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.60

ImmuCell Corporation (ICCC) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- β€’ HOLD / WATCH Cap $93.2M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ICCC Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ICCC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, ImmuCell Corporation (NASDAQ: ICCC) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $10.56 (+2.92% 1D, market cap $93.2M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 8/20. Across 1015 tracked Health Care issuers, ICCC ranks #174 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ICCC compare to IMDX and TKNO in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), ICCC carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of 41.4%, and ROIC of 4.2%. By comparison, IMDX (Insight Molecular Diagnostics Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $96.9M) and TKNO (Alpha Teknova Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -21.3%, cap $454.1M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ICCC?
β–Ό

Per ICCC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000811641), ImmuCell Corporation generated $27.6M in revenue (+4.3% YoY), -$1.0M in net income, and $1.2M in free cash flow against $42.5M in total assets and $7.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $10.60 (+0.34%)🧬 Disciplined Float (+1.08% YoY Shares)βš™οΈ Cash Engine: 11/20 (D+) β€’ 4.4% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY β€’ 53.1% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERHOLD / WATCH β€’ C-
025507510059
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D Β· Rk B
Cash (11)Whales (11)SEC (13)Macro (16)CEO (8)
Each axis scored 0–20
12M PRICE TARGET CONE+0.5% Base Target
$13 Bull$11 Base$8 Bear
πŸ“¬ FREE ICCC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ICCC)Realized 20D OHLCV Swing Band: Β±5.1%
Deterministic 5-Pillar Attribution (59/100 Composite)
πŸ” WHY ICCC SCORES 59/100 (C-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Macro Regime Fit+16/20 pts (27% of score)

FRED Regime Γ— Technicals: 80% of 52W Range β€’ RSI-14 at 50.4 (NEUTRAL RANGE)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 4.28 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 8/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution8/20 pts (-12 pt drag)

Disciplined Float (+1.08% YoY Shares) & executive Form 4 sales trim 12 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
67
Grade B-$10.79-3.2% Next Q
Q2 (-2Q)
64
Grade C+$10.45-1.8% Next Q
Q3 (-1Q)
62
Grade C+$10.26+2.9% Next Q
Current
59
Grade C-$10.56+0.2% Hist 90D Ξ±
Trajectory: B- (67) β†’ C- (59)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the ICCC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 59/100 (C-) score, ICCC faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (+1.08% YoY Shares) β€” any gross margin slip below 38.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($10.05) or 200D SMA ($8.90) invalidates the momentum regime and cuts Target Base ($10.61) toward Bear Floor ($8.28).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ICCCβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œICCC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 59%NO 41%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±5.1%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ICCC)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ICCC.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating ICCC & AI Leaders Without Chasing Tops

  • βœ“Institutional whale strikes & implied earnings move audit on ICCC
  • βœ“How disciplined traders manage risk using pre-published trigger & invalidation levels
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ICCC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.10%⚑ TESTING RESISTANCE
2026-11-03O $10.32H $10.56L $10.26C $10.56VOL 11.0K
RES: $10.76SUP: $9.64SMA50: $10.05SMA200: $8.90
$12.50$10.83$9.17$7.50$5.83RES $10.76SUP $9.64$10.562026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ICCC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ICCC Butterfly Map β†’ + Track ICCC β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
33.5%/yr Implied 5Y Growth

vs. +4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ICCC today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ICCC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ICCC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ICCC)

Health Care Rank #174 of 1015 βš”οΈ IMDX vs ICCC Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ICCC vs. IMDX, TKNO, NNNN, MYGN)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, ImmuCell Corporation (ICCC) ranks #174 by composite RQD confidence (59/100, grade C-) and #662 by equity capitalization ($93.2M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. ICCC currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ICCC ACTIVE
ImmuCell Corporation
C- 59/100 β€” 41.4% 4.2% +2.92% $93.2M Benchmark Subject
IMDX
Insight Molecular Diagnostics Inc.
E 25/100 β€” 56.7% -35.0% -3.38% $96.9M /imdx-vs-iccc β†’
TKNO
Alpha Teknova Inc.
D- 42/100 β€” 33.2% -21.3% -4.75% $454.1M /tkno-vs-iccc β†’
NNNN
Anbio Biotechnology (Class A)
D- 35/100 83.6x 87.2% 17.0% +4.46% $483.5M /nnnn-vs-iccc β†’
MYGN
Myriad Genetics Inc.
D 47/100 β€” 69.9% -35.0% -7.87% $607.4M /mygn-vs-iccc β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0000811641 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ImmuCell Corporation (ICCC) reported GAAP revenue of $27.6M (+4.3% vs. FY2024 revenue of $26.5M , and +58.2% cumulative change since FY2023) , GAAP net income of -$1.0M, operating cash flow of $2.5M, and free cash flow of $1.2M (+1236.0% YoY). On the balance sheet, ICCC closed FY2025 with $42.5M in total assets against $7.5M in total debt (Altman Z-Score: 4.28, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $27.6M -$1.0M $2.5M $1.2M $42.5M $7.5M
FY2024 (FY) 2024-12-31 $26.5M -$2.2M $357.9K -$107.8K $45.1M $9.0M
FY2023 (FY) 2023-12-31 $17.5M -$5.8M -$4.7M -$4.7M β€” β€”

3. ICCC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ICCC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, ImmuCell Corporation (NASDAQ: ICCC) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $10.56 (+2.92% 1D, market cap $93.2M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 8/20. Across 1015 tracked Health Care issuers, ICCC ranks #174 in composite RQD confidence.

How does ICCC compare to IMDX and TKNO in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), ICCC carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of 41.4%, and ROIC of 4.2%. By comparison, IMDX (Insight Molecular Diagnostics Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $96.9M) and TKNO (Alpha Teknova Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -21.3%, cap $454.1M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ICCC?

Per ICCC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000811641), ImmuCell Corporation generated $27.6M in revenue (+4.3% YoY), -$1.0M in net income, and $1.2M in free cash flow against $42.5M in total assets and $7.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ICCC trading relative to its 50-day, 200-day, and 52-week technical levels?

ICCC last traded at $10.56 (+2.92% on volume of 2,036 shares), positioning the stock +5.07% above its 50-day simple moving average ($10.05) and +18.65% above its 200-day simple moving average ($8.90). Across its 52-week range of $4.52 to $12.10, ICCC sits at the 79.7% percentile with a 14-day RSI of 50.4 (NEUTRAL RANGE) and an implied next-earnings move of Β±5.1% ($10.02 to $11.10).

Direct Sub-Reports: ICCC RQD Cockpit ICCC 12M Forecast ICCC Earnings & Move ICCC Dividends & DRIP ICCC Insiders & 13F ICCC Whale Options ICCC Profit Sankey ICCC News & Why
ROARABLE RATING BRIEF β€’ RQD 59/100 (C-) βœ“ SEC XBRL & RQD VERIFIED

ICCC β€” ImmuCell Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

ImmuCell Corporation (ICCC) earns a live Roarable RQD composite score of 59/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $10.56 (+2.92% 1D, market capitalization $93.2M).

  • Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of 4.2%, gross margin of 41.4%, operating margin of 6.0%, and free cash flow yield of 1.31%.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (8/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (16/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of 4.28, Piotroski F-Score of 8/9, and Debt/Equity of 0.28x.

2. Business Model, Unit Margins & SEC Financial Trajectory

ImmuCell Corporation is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry. The profile characterizes the company as a biotechnology diagnostic-substances business with a market capitalization of $0.1B. Revenue reported for FY 2025 was $27.6M, and gross margin is 41.4% per the market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), ImmuCell Corporation (ICCC) reported $27.6M in annual revenue (up from $26.5M in FY2024, +4.3% YoY) and -$1.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($17.5M revenue, -$5.8M net income) through FY2025, ICCC scaled operating cash flow to $2.5M and free cash flow to $1.2M, backed by $42.5M in total assets against $7.5M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (C- β€’ RQD 59/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 1.31% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $4.52 – $12.10 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation and 35.9x EV/EBITDA against 6.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

There are no upstream or downstream links and no proprietary signals recorded. Sector correlations and 2nd-order bottlenecks cannot be identified from the source data.

  • Key Question #1: Can ICCC sustain or expand its 6.0% operating margin and 4.2% ROIC against Biotechnology: In Vitro & In Vivo Diagnostic Substances peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $27.6M and free cash flow of $1.2M, how will capital allocation balance growth reinvestment against $7.5M in total debt?
  • Key Question #3: How sensitive is ICCC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ICCC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ImmuCell Corporation (ICCC) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ICCC Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ICCC Bull vs. Bear Conversation Board β€” What's Your Call at $10.56?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ICCC 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ICCC:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER β€’ Options Flow Specialist πŸ‚ BULLISH 🎯 Target: $11.90 (+16.0%)
πŸ“Œ Pinned Debate

Operating income swung from a -$5.7M loss in FY 2023 to $1.6M in FY 2025 while debt fell from $9.0M to $7.5M, with a Piotroski F-Score

Picked up a starter position in ICCC in my $100K Virtual Cash book at $10.26. Operating income swung from a -$5.7M loss in FY 2023 to $1.6M in FY 2025 while debt fell from $9.0M to $7.5M, with a Piotroski F-Score of 8/9 and Altman Z-Score of 4.28.. Trading inside a $4.52–$12.10 52-week range with 1.31% FCF yield gives solid downside support if Biotechnology: In Vitro & In Vivo Diagnostic Substances multiples expand this quarter.

CapAlloc_Nerd πŸ‚ BULL

@DeltaGamma_99 Agree on the RQD 59/100 quality, though with 1.0 beta I'm scaling in with half-size at $10.26 and keeping dry powder in case we test $9.54.

ME MeanReversion_88 RQD DEBATE OPENER β€’ Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $7.80 (-24.0%)
Spot @ $10.26

Net margin is -3.8%, ROIC is only 4.2%, and FCF yield is 1.31% against an EV/EBITDA of 35.9, leaving the valuation resting on earnings

Fading this rally in ICCC at $10.26. Net margin is -3.8%, ROIC is only 4.2%, and FCF yield is 1.31% against an EV/EBITDA of 35.9, leaving the valuation resting on earnings that reported results do not yet show.. With a beta of 1.0 and the stock sitting at $10.26 (52-wk range $4.52–$12.10), the easy multiple expansion is already priced in.

LIVE TAPE